ZOGENIX, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2018-12-03: Form 8-K; Period of report 2018-12-03; Description 8.01 Other Events; Details 8.01.
- 2018-11-08: Form 8-K; Period of report 2018-11-08; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2018-10-05: Form 8-K; Period of report 2018-10-01; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2018-08-08: Form 8-K; Period of report 2018-08-07; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2018-12-03 | 8-K | 2018-12-03 | 8.01 Other Events | 8.01 On December 3, 2018, Zogenix, Inc. (the “Company”) reported that late-breaking data will be presented on the use of its investigational drug, FINTEPLA (ZX008; low-dose fenfluramine), in children and young adults with Dravet syndrome. | d658820d8k.htm |
| 2018-11-08 | 8-K | 2018-11-08 | 2.02 Results of Operations and Financial Condition | 2.02 On November 8, 2018, Zogenix, Inc. issued a press release announcing its financial results for the third quarter September 30, 2018. | a20180930er8-k.htm |
| 2018-10-05 | 8-K | 2018-10-01 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 1.02 Concurrently with the entry into the New Lease, the Company entered into a lease termination agreement (the “Lease Termination”), dated October 1, 2018, with Emery Station for the termination of the Company’s Existing Lease. 2.03 The information set forth under “Item 1.01 - Entry into a Material Definitive Agreement” is incorporated in this Item 2.03 by reference. | zgnx-20181005x8k.htm |
| 2018-08-08 | 8-K | 2018-08-07 | 8.01 Other Events | 8.01 On August 7, 2018, Zogenix, Inc. (“Zogenix” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Merrill Lynch, Pierce, Fenner & Smith Incorporated, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated, as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale of 6,000,000 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). | d605176d8k.htm |
| 2018-08-06 | 8-K | 2018-08-06 | 2.02 Results of Operations and Financial Condition | 2.02 On August 6, 2018, Zogenix, Inc. issued a press release announcing its financial results for the second quarter June 30, 2018. | a201806308-k.htm |
| 2018-07-12 | 8-K | 2018-07-12 | 8.01 Other Events | 8.01 On July 12, 2018, Zogenix, Inc. (the “Company”) reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome. | d489105d8k.htm |
| 2018-07-02 | 8-K | 2018-07-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 2, 2018, Zogenix, Inc. (“Zogenix” or the “Company”) announced the appointment of Ashish Sagrolikar as Executive Vice President and Chief Commercial Officer, effective July 2, 2018. | zgnx-201807028xk.htm |
| 2018-05-23 | 8-K | 2018-05-23 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Stockholders of Zogenix, Inc. (the “Company”) was held on May 23, 2018. | zgnx-2018proxyform8xk.htm |
| 2018-05-09 | 8-K | 2018-05-09 | 2.02 Results of Operations and Financial Condition | 2.02 On May 9, 2018, Zogenix, Inc. issued a press release announcing its financial results for the first quarter March 31, 2018. | a201803318-k.htm |
| 2018-03-06 | 8-K | 2018-03-06 | 2.02 Results of Operations and Financial Condition | 2.02 On March 6, 2018, Zogenix, Inc. issued a press release announcing its financial results for the fourth quarter and full-year ended December 31, 2017. | zgnx-12312017x8k.htm |
| 2018-02-06 | 8-K | 2018-02-06 | 8.01 Other Events | 8.01 On February 6, 2018, Zogenix, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (the “FDA”) has granted Breakthrough Therapy Designation for the Company’s investigational product, ZX008 (low-dose fenfluramine), for the treatment of seizures associated with Dravet syndrome. | d538058d8k.htm |
| 2018-02-02 | 8-K | 2018-01-31 | 8.01 Other Events | 8.01 On January 31, 2018, Zogenix, Inc. (the “Company”) announced that the last patient had been randomized into the treatment period of Study 1504, its second Phase 3 clinical trial evaluating ZX008 (low-dose fenfluramine) as an adjunctive treatment for seizures in children and young adults with Dravet syndrome. | d536825d8k.htm |